Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12314560 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRMAPK1ALDH1A1KDM4E | |
| SCHEMBL1232285 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRMAPK1ALDH1A1KDM4E | |
| SCHEMBL14551971 | 0.70 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRMAPK1ALDH1A1KDM4E | |
| SCHEMBL14551969 | 0.70 | SMN1; SMN2 (0.42) | SMN1; SMN2TSHRMAPK1ALDH1A1KDM4E | |
| SCHEMBL12314563 | 0.69 | SMN1; SMN2 (0.39) | SMN1; SMN2TSHRMAPK1ALDH1A1HSD11B1 | |
| SCHEMBL2898127 | 0.68 | HSD11B1 (0.52) | SMN1; SMN2TSHRMAPK1ALDH1A1HSD17B10 | |
| SCHEMBL3772574 | 0.67 | HSD11B1 (0.39) | SMN1; SMN2TSHRMAPK1ALDH1A1HPGD | |
| SCHEMBL27934023 | 0.66 | MAPK1 (0.44) | SMN1; SMN2TSHRMAPK1ALDH1A1ATM | |
| SCHEMBL5051902 | 0.65 | TSHR (0.54) | SMN1; SMN2TSHRMAPK1ALDH1A1KDM4E | |
| SCHEMBL3359896 | 0.64 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRMAPK1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263630-B2 | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263630-B2 | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263630-B2 | 1,2,3-triazoles as 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100324104-A1 | 1,2,3-TRIAZOLES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-20100324104-A1 | 1,2,3-TRIAZOLES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-20100324104-A1 | 1,2,3-TRIAZOLES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-12-23 | — | — | US | disclosed |
| WO-2009102761-A1 | 1,2,3-TRIAZOLES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102761-A1 | 1,2,3-TRIAZOLES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324104-A1 | 1,2,3-TRIAZOLES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD11B1, HSD17B1, HSD3B1 | SMN1; SMN2 2961/4885TSHR 2277/4885MAPK1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.